dichloroacetic acid has been researched along with carboplatin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, GL; Li, N; Liu, L; Sun, H; Wu, XR; Zhang, B; Zhang, ZF | 1 |
| Beller, M; Hein, JI; Junghanß, C; Murua Escobar, H; Nolte, I; Schille, JT; Weiner, F; Wu, XF | 1 |
2 other study(ies) available for dichloroacetic acid and carboplatin
| Article | Year |
|---|---|
Selective protection of normal cells during chemotherapy by RY4 peptides.
Topics: Animals; Antineoplastic Agents; Antioxidants; Carboplatin; Catalase; Cell Line, Tumor; Cell Survival; Cytoprotection; Dichloroacetic Acid; Doxorubicin; Humans; Mice, Nude; Myocardium; Neoplasms; Oxidative Stress; Peptides; Protein Binding; Proteomics; Rats; Xenograft Model Antitumor Assays | 2014 |
Evaluation of combination protocols of the chemotherapeutic agent FX-9 with azacitidine, dichloroacetic acid, doxorubicin or carboplatin on prostate carcinoma cell lines.
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Carboplatin; Cell Count; Cell Line, Tumor; Cell Survival; Dichloroacetic Acid; Doxorubicin; Drug Synergism; Humans; Isoquinolines; Male; Prostatic Neoplasms | 2021 |